Enzymatica publ AB
Enzymatica AB (publ), a life science company, develops and sells medical devices for infection-related diseases. The company's product includes ColdZyme, a mouth spray that protects against the upper respiratory viruses that can cause cold and flu symptoms. It also provides enzyme formulations for skin care. The company was incorporated in 2007 and is headquartered in Lund, Sweden.
Enzymatica publ AB (ENZY) - Net Assets
Latest net assets as of September 2025: Skr135.68 Million SEK
Based on the latest financial reports, Enzymatica publ AB (ENZY) has net assets worth Skr135.68 Million SEK as of September 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (Skr149.24 Million) and total liabilities (Skr13.56 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | Skr135.68 Million |
| % of Total Assets | 90.92% |
| Annual Growth Rate | 61.3% |
| 5-Year Change | 65.37% |
| 10-Year Change | 702.22% |
| Growth Volatility | 422.03 |
Enzymatica publ AB - Net Assets Trend (2007–2024)
This chart illustrates how Enzymatica publ AB's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Enzymatica publ AB (2007–2024)
The table below shows the annual net assets of Enzymatica publ AB from 2007 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | Skr176.37 Million | +130.22% |
| 2023-12-31 | Skr76.61 Million | -39.34% |
| 2022-12-31 | Skr126.29 Million | +1.06% |
| 2021-12-31 | Skr124.97 Million | +17.18% |
| 2020-12-31 | Skr106.65 Million | -10.53% |
| 2019-12-31 | Skr119.20 Million | -25.34% |
| 2018-12-31 | Skr159.66 Million | +44.23% |
| 2017-12-31 | Skr110.70 Million | -22.07% |
| 2016-12-31 | Skr142.04 Million | +546.09% |
| 2015-12-31 | Skr21.98 Million | -64.78% |
| 2014-12-31 | Skr62.42 Million | +296.90% |
| 2013-12-31 | Skr15.73 Million | +11.87% |
| 2012-12-31 | Skr14.06 Million | +324.23% |
| 2011-12-31 | Skr3.31 Million | -24.70% |
| 2010-12-31 | Skr4.40 Million | +588.20% |
| 2009-12-31 | Skr-901.48K | -26.61% |
| 2008-12-31 | Skr-712.00K | -1469.23% |
| 2007-12-31 | Skr52.00K | -- |
Equity Component Analysis
This analysis shows how different components contribute to Enzymatica publ AB's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 49055100000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | Skr9.71 Million | 5.50% |
| Other Comprehensive Income | Skr1.31 Million | 0.75% |
| Other Components | Skr655.90 Million | 371.89% |
| Total Equity | Skr176.37 Million | 100.00% |
Enzymatica publ AB Competitors by Market Cap
The table below lists competitors of Enzymatica publ AB ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Kindly MD, Inc. Common Stock
NASDAQ:KDLY
|
$20.95 Million |
|
WITTED MEGACORP OYJ EO 1
F:8OS
|
$20.95 Million |
|
Munjal Auto Industries Limited
NSE:MUNJALAU
|
$20.95 Million |
|
Enogia SAS
PA:ALENO
|
$20.95 Million |
|
Uni Charm Indonesia PT
JK:UCID
|
$20.94 Million |
|
Guyoung Technology Co. Ltd
KQ:053270
|
$20.94 Million |
|
PJ Electronics Co. Ltd
KQ:006140
|
$20.94 Million |
|
Chengdu PUTIAN Telecommunications Cable Company Limited
F:CUEH
|
$20.94 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Enzymatica publ AB's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 76,609,000 to 176,369,000, a change of 99,760,000 (130.2%).
- Net loss of 53,179,000 reduced equity.
- Share repurchases of 159,262,000 reduced equity.
- New share issuances of 159,262,000 increased equity.
- Other comprehensive income increased equity by 1,101,999.
- Other factors increased equity by 151,837,001.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | Skr-53.18 Million | -30.15% |
| Share Repurchases | Skr159.26 Million | -90.3% |
| Share Issuances | Skr159.26 Million | +90.3% |
| Other Comprehensive Income | Skr1.10 Million | +0.62% |
| Other Changes | Skr151.84 Million | +86.09% |
| Total Change | Skr- | 130.22% |
Book Value vs Market Value Analysis
This analysis compares Enzymatica publ AB's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 2.40x
- The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2009-12-31 | Skr-0.03 | Skr2.20 | x |
| 2011-12-31 | Skr0.26 | Skr2.20 | x |
| 2012-12-31 | Skr0.76 | Skr2.20 | x |
| 2013-12-31 | Skr0.76 | Skr2.20 | x |
| 2014-12-31 | Skr2.41 | Skr2.20 | x |
| 2015-12-31 | Skr0.78 | Skr2.20 | x |
| 2016-12-31 | Skr2.13 | Skr2.20 | x |
| 2017-12-31 | Skr1.21 | Skr2.20 | x |
| 2018-12-31 | Skr1.68 | Skr2.20 | x |
| 2019-12-31 | Skr0.83 | Skr2.20 | x |
| 2020-12-31 | Skr0.75 | Skr2.20 | x |
| 2021-12-31 | Skr0.85 | Skr2.20 | x |
| 2022-12-31 | Skr0.76 | Skr2.20 | x |
| 2023-12-31 | Skr0.43 | Skr2.20 | x |
| 2024-12-31 | Skr0.92 | Skr2.20 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Enzymatica publ AB utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -30.15%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -116.68%
- • Asset Turnover: 0.23x
- • Equity Multiplier: 1.11x
- Recent ROE (-30.15%) is above the historical average (-57.63%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2009 | 0.00% | -121.08% | 0.13x | 0.00x | Skr-99.95K |
| 2011 | -150.48% | -856.87% | 0.13x | 1.40x | Skr-5.32 Million |
| 2012 | -53.83% | -845.59% | 0.06x | 1.14x | Skr-8.97 Million |
| 2013 | -103.05% | -154.52% | 0.40x | 1.65x | Skr-17.78 Million |
| 2014 | -51.89% | -169.93% | 0.26x | 1.16x | Skr-38.64 Million |
| 2015 | -185.72% | -146.28% | 0.64x | 1.99x | Skr-43.03 Million |
| 2016 | -31.76% | -123.36% | 0.22x | 1.15x | Skr-59.17 Million |
| 2017 | -28.50% | -52.90% | 0.44x | 1.21x | Skr-42.48 Million |
| 2018 | -26.67% | -81.01% | 0.28x | 1.16x | Skr-58.55 Million |
| 2019 | -34.38% | -66.84% | 0.42x | 1.24x | Skr-52.90 Million |
| 2020 | -12.40% | -11.88% | 0.69x | 1.52x | Skr-23.89 Million |
| 2021 | -36.32% | -79.30% | 0.36x | 1.26x | Skr-57.89 Million |
| 2022 | -54.36% | -140.27% | 0.28x | 1.38x | Skr-81.29 Million |
| 2023 | -64.91% | -97.69% | 0.40x | 1.64x | Skr-57.39 Million |
| 2024 | -30.15% | -116.68% | 0.23x | 1.11x | Skr-70.82 Million |
Industry Comparison
This section compares Enzymatica publ AB's net assets metrics with peer companies in the Drug Manufacturers - Specialty & Generic industry.
Industry Context
- Industry: Drug Manufacturers - Specialty & Generic
- Average net assets among peers: $96,957,935
- Average return on equity (ROE) among peers: -55.82%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Enzymatica publ AB (ENZY) | Skr135.68 Million | 0.00% | 0.10x | $20.94 Million |
| BioGaia AB (publ) (BIOG-B) | $230.35 Million | 33.15% | 0.21x | $714.80 Million |
| Dicot AB (DICOT) | $73.40 Million | -109.26% | 0.16x | $55.17 Million |
| Enorama Pharma AB (ERMA) | $17.02 Million | -96.01% | 1.28x | $566.46K |
| Gabather AB (publ) (GABA) | $10.96 Million | -155.04% | 0.40x | $732.74K |
| Klaria Pharma Holding AB (KLAR) | $-452.69K | 0.00% | 0.00x | $15.08 Million |
| Moberg Pharma AB (publ) (MOB) | $76.79 Million | -8.31% | 0.20x | $38.42 Million |
| Nanexa AB (NANEXA) | $101.53 Million | -11.22% | 0.36x | $39.92 Million |
| Newbury Pharmaceuticals AB (NEWBRY) | $51.92 Million | -29.67% | 0.75x | $559.69K |
| Orexo AB (ORX) | $311.10 Million | -126.01% | 0.76x | $45.88 Million |